Finding the Right Way to Target EGFR in Glioblastomas; Lessons from Lung Adenocarcinomas

The gene is one of the most frequently mutated and/or amplified gene both in lung adenocarcinomas (LUAD) and in glioblastomas (GBMs). Although both tumor types depend on the mutation for growth, clinical benefit of EGFR tyrosine kinase inhibitors (TKIs) has only been observed in LUAD patients and, t...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Cancers 2018-12, Vol.10 (12), p.489
Hauptverfasser:	Gao, Ya, Vallentgoed, Wies R, French, Pim J
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!